The Rise of cfHPV-DNA as a Biomarker for HPV-Associated OPSCC
Time: 3:10 pm
day: Day Two Track B
Details:
- Assess patients’ trial eligibility, by determining patients’ HPV status and subtype with a simple blood draw.
- Gain real-time insights into treatment response, by assessing dynamic changes in cfHPV-DNA quantitatively over the course of treatment.
- Detect recurrent disease — including distant recurrence — early, with detection that precedes the current standard of care.
